Chemotherapy News and Research

Latest Chemotherapy News and Research

Tissue stiffening linked to disease progression in HER2-negative breast cancer

A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly cause disease progression and metastasis, leading to detrimental outcomes for patients.

22 Oct 2024

Physical tests offer prognostic insights for lung cancer patients

A study of patients with metastatic lung cancer by researchers based in Brazil and the United States has found that their performance in simple physical tests such as sitting down, standing and walking can help physicians arrive at a prognosis and approach to treatment.

22 Oct 2024

MRI can spare many patients with rectal cancer from invasive surgery

Magnetic resonance imaging (MRI) can spare many patients with rectal cancer from invasive surgery that can carry lifelong side effects, new research indicates.

22 Oct 2024

Study reveals complex role of polyploidy in cancer and treatment resistance

Polyploidy is a state where a cell contains more copies of the genetic material than the usual "diploid" cell, which contains two copies.

21 Oct 2024

Unraveling the mechanisms of B-cell maturation in blood cancer

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic Leukaemia (B-ALL) next year in Spain, according to the latest projections from the Spanish network of cancer registries (REDECAN).

21 Oct 2024

Aerobic exercise boosts cognitive function in breast cancer patients

Many women who receive chemotherapy experience a decreased ability to remember, concentrate, and/or think-;commonly referred to as "chemo-brain" or "brain fog"-;both short- and long-term.

21 Oct 2024

Polyploidy can be a double-edged sword in cancer

Polyploidy is a state where a cell contains more copies of the genetic material than the usual "diploid" cell, which contains two copies.

21 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

Studies reveal the financial fallout of cancer survivors

A diagnosis of cancer can take a toll on more than a person's health. Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston found that financial fallout can follow patients with cancer and their families in the form of bankruptcy, lower credit scores, and other forms of financial challenges years after a cancer diagnosis.

18 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

ALS drug shows promise in targeting glioblastoma stem cells

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable.

17 Oct 2024

New diagnostic test aims for same-day detection of leptomeningeal disease

With time being of the essence for patients facing one of cancer's most dire complications, UCLA researchers are working to create a new test to detect cancer's spread to the central nervous system on the same day as the doctor's visit.

17 Oct 2024

Edaravone shows promise in targeting brain tumor stem cells

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.

17 Oct 2024

FDA-approved breast cancer drug shows promise for appendix cancer

Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of appendix cancer.

16 Oct 2024

Immunotherapy sets new standard for Hodgkin lymphoma care

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease.

16 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

Short course chemotherapy boosts survival rates in cervical cancer patients

Cervical cancer patients were significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation, finds a clinical trial led by researchers from UCL and UCLH.

15 Oct 2024

Breakthrough in understanding microtubule formation in cells

Inside every cell, a network of tiny filaments, called the microtubule cytoskeleton, helps maintain the cell's shape, allows it to divide, and transports vital materials from one part of the cell to another.

15 Oct 2024

Case Western Reserve University receives grant to investigate AML treatment for veterans

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia (AML) in military Veterans.

15 Oct 2024

Extrachromosomal DNA in more aggressive cancers could be targets for future therapies

Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher concentration of a specific kind of DNA — extrachromosomal or ecDNA — in more aggressive and advanced cancers that could mark them as targets for future therapies.

15 Oct 2024